Tag: when ins ASCO 2021
Takeda’s Flagship Product Panitumumab (PAN)+mFOLFOX6 Versus bevacizumab (BEV) + mFOLFOX6
Takeda’s Flagship Product Panitumumab (PAN)+mFOLFOX6 Versus bevacizumab (BEV) + mFOLFOX6
0
0
0
8 Jul, 10:01 AM
